Startups

Ultromics

Ultromics develops AI software that analyzes routine echocardiograms to help clinicians identify heart failure with preserved ejection fraction and screen for cardiac amyloidosis. Its EchoGo Heart Failure and EchoGo Amyloidosis products evaluate cardiac ultrasound images, generate disease-related findings and probability scores, and deliver results through existing hospital imaging workflows. The Oxford University spinout combines cardiovascular research and machine learning to support earlier assessment and treatment pathways, using secure cloud integration with ultrasound systems and PACS.

Founded 2017

Team

Amir HasanChief Operating Officer

Gary WoodwardChief Product Officer

Helen RouthNon-Executive Director

Jaco JacobsChief Regulatory and Compliance Officer

Nancy SpagouChief Experience Officer

Patricia PellikkaClinical Research Collaborator

Paul LeesonAcademic Founder and Non-Executive Director

Roger OwensChief Commercial Officer

Ross UptonFounder and Chief Executive Officer

Ryan LynchBoard Observer

Investments

$—2025-12-17	0 participations
$55M2025-07-31	Lightrock, Oxford Science Enterprises, GV, The Blue Venture Fund, UPMC Enterprises
$—Unknown date	GT Healthcare Capital Partners
$—Unknown date	NovaCapital (Italy)

team@apexlogos.ai22 hours ago
NovaCapital own portfolio misspells Ultromics as Utromics in an image label but links its authentic ultromics.com domain. This establishes an undated holding with unknown amount, stage and lead status. NovaCapital is not individually named in the July31,2025 Series C or December17,2025 AHA strategic investment, so is not assigned to either financing. https://www.novacapital.eu/en/portfolio.html July31,2025 issuer and original issuer-provided US PRNewswire release announce $55 million Series C; USD normalization is corroborated by Venionaire DealMatrix explicitly reporting USD55m on August4,2025 and Rothschild & Co August2025 growth-equity report filepage20. No exchange-rate conversion is applied. Co-leads L&G, Allegis Capital and Lightrock; other named participants Oxford Science Enterprises, GV, Blue Venture Fund, Oxford University, UCM Ventures and UPMC Enterprises. Oxford University is not the Oxford University Innovation Fund; Allegis Capital is not AllegisCyber. Only existing canonically identified participants are linked. https://www.prnewswire.com/news-releases/ultromics-lands-55m-series-c-to-tackle-undiagnosed-heart-failure-at-scale-302517834.html December17,2025 company release confirms an AHA Go Red for Women Venture Fund investment of unknown amount/stage. The dated financing is recorded with source; its investor participation awaits complete missing institution/profile identity work, rather than creating a bare investor or assuming a Series C extension. Paul Leeson own detailed current biography says Academic Founder/Non-Executive Director, whereas leadership roster/footer says Founder/CMO. The specific person biography role is used and the source conflict preserved. Patricia Pellikka is a named clinical research collaborator, not an asserted employee or director. Blue Venture Fund’s current Ryan Lynch biography confirms his board observer role, not director seat or personal check.